7.6(top 2%)
impact factor
7.0K(top 5%)
183.5K(top 2%)
153(top 2%)
7.8(top 2%)
extended IF
all documents
doc citations
235(top 2%)

Top Articles

1The FDA-approved drug ivermectin inhibits the replication of SARS-CoV-2 in vitroAntiviral Research20201,567
2The spike glycoprotein of the new coronavirus 2019-nCoV contains a furin-like cleavage site absent in CoV of the same cladeAntiviral Research20201,450
3Present and future arboviral threatsAntiviral Research20101,162
4Favipiravir (T-705), a novel viral RNA polymerase inhibitorAntiviral Research2013840
5Remdesivir, lopinavir, emetine, and homoharringtonine inhibit SARS-CoV-2 replication in vitroAntiviral Research2020737
6The SARS-coronavirus papain-like protease: Structure, function and inhibition by designed antiviral compoundsAntiviral Research2015680
7Coronavirus membrane fusion mechanism offers a potential target for antiviral developmentAntiviral Research2020635
8Crimean-Congo hemorrhagic fever: History, epidemiology, pathogenesis, clinical syndrome and genetic diversityAntiviral Research2013613
9Crimean?Congo hemorrhagic feverAntiviral Research2004582
10Zika virus: History, emergence, biology, and prospects for controlAntiviral Research2016571
11Antiviral effect of catechins in green tea on influenza virusAntiviral Research2005550
12A three-dimensional model to analyze drug-drug interactionsAntiviral Research1990543
13Nsp3 of coronaviruses: Structures and functions of a large multi-domain proteinAntiviral Research2018542
14Antiviral activity of phosphonylmethoxyalkyl derivatives of purine and pyrimidinesAntiviral Research1987518
15Protease inhibitors targeting coronavirus and filovirus entryAntiviral Research2015513
16Tick-borne encephalitisAntiviral Research2003494
17Identification of natural compounds with antiviral activities against SARS-associated coronavirusAntiviral Research2005474
18Of chloroquine and COVID-19Antiviral Research2020468
19The SARS coronavirus nucleocapsid protein – Forms and functionsAntiviral Research2014436
20Herpes simplex encephalitis: Adolescents and adultsAntiviral Research2006434
21Anti-SARS coronavirus 3C-like protease effects of Isatis indigotica root and plant-derived phenolic compoundsAntiviral Research2005430
22Successful treatment of advanced Ebola virus infection with T-705 (favipiravir) in a small animal modelAntiviral Research2014428
23The flavivirus NS1 protein: Molecular and structural biology, immunology, role in pathogenesis and application as a diagnostic biomarkerAntiviral Research2013425
24Type 1 interferons as a potential treatment against COVID-19Antiviral Research2020425
25Crimean–Congo hemorrhagic feverAntiviral Research2004416
26Nitazoxanide: A first-in-class broad-spectrum antiviral agentAntiviral Research2014415
27Antiviral drugs for cytomegalovirus diseasesAntiviral Research2006407
28Emodin blocks the SARS coronavirus spike protein and angiotensin-converting enzyme 2 interactionAntiviral Research2007400
29Broad spectrum antiviral remdesivir inhibits human endemic and zoonotic deltacoronaviruses with a highly divergent RNA dependent RNA polymeraseAntiviral Research2019398
30T-705 (favipiravir) and related compounds: Novel broad-spectrum inhibitors of RNA viral infectionsAntiviral Research2009393
31Chikungunya fever: Epidemiology, clinical syndrome, pathogenesis and therapyAntiviral Research2013388
32The development of antiretroviral therapy and its impact on the HIV-1/AIDS pandemicAntiviral Research2010386
33Antiviral activities of lactoferrinAntiviral Research2001383
34Arbidol as a broad-spectrum antiviral: An updateAntiviral Research2014375
35Antiviral activities of type I interferons to SARS-CoV-2 infectionAntiviral Research2020374
36Proteolytic activation of the SARS-coronavirus spike protein: Cutting enzymes at the cutting edge of antiviral researchAntiviral Research2013354
37The evolution of nucleoside analogue antivirals: A review for chemists and non-chemists. Part 1: Early structural modifications to the nucleoside scaffoldAntiviral Research2018352
38The role of non-nucleoside reverse transcriptase inhibitors (NNRTIs) in the therapy of HIV-1 infection1Presented at the Eleventh International Conference on Antiviral Research, San Diego, CA, 5–10 April 1998.1Antiviral Research1998350
39The H274Y mutation in the influenza A/H1N1 neuraminidase active site following oseltamivir phosphate treatment leave virus severely compromised both in vitro and in vivoAntiviral Research2002348
40Inhibition of the infectivity of influenza virus by tea polyphenolsAntiviral Research1993341
41Ecology, evolution and classification of bat coronaviruses in the aftermath of SARSAntiviral Research2014340
42Accessory proteins of SARS-CoV and other coronavirusesAntiviral Research2014339
43Non-nucleoside reverse transcriptase inhibitors (NNRTIs), their discovery, development, and use in the treatment of HIV-1 infection: A review of the last 20 years (1989–2009)Antiviral Research2010334
44Chikungunya: Evolutionary history and recent epidemic spreadAntiviral Research2015331
45Inhibitory effect of dextran sulfate and heparin on the replication of human immunodeficiency virus (HIV) in vitroAntiviral Research1987326
46Anti-hepatitis B virus activity of chlorogenic acid, quinic acid and caffeic acid in vivo and in vitroAntiviral Research2009326
47Resistance of influenza viruses to neuraminidase inhibitors — a reviewAntiviral Research2000316
48Nucleoside and nucleotide HIV reverse transcriptase inhibitors: 25 years after zidovudineAntiviral Research2010314
49T-cell immunity of SARS-CoV: Implications for vaccine development against MERS-CoVAntiviral Research2017314
50African swine feverAntiviral Research2019313